FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002605455> ?p ?o ?g. }

• W2002605455 endingPage "475" @default.
• W2002605455 startingPage "470" @default.
• W2002605455 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Aug 2001COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORS ARIS GIANNOPOULOS, THEODOROS MANOUSAKAS, ANTONIA GOUNARI, CONSTANTINOS CONSTANTINIDES, HELEN CHOREMI-PAPADOPOULOU, and CONSTANTINOS DIMOPOULOS ARIS GIANNOPOULOSARIS GIANNOPOULOS More articles by this author , THEODOROS MANOUSAKASTHEODOROS MANOUSAKAS More articles by this author , ANTONIA GOUNARIANTONIA GOUNARI More articles by this author , CONSTANTINOS CONSTANTINIDESCONSTANTINOS CONSTANTINIDES More articles by this author , HELEN CHOREMI-PAPADOPOULOUHELEN CHOREMI-PAPADOPOULOU More articles by this author , and CONSTANTINOS DIMOPOULOSCONSTANTINOS DIMOPOULOS More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65965-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared overall sensitivity and specificity of the urinary bladder cancer antigen enzyme-linked immunosorbent assay (UBC, IDL Biotech, Sollentuna, Sweden), BTA stat test (Bion Diagnostic Sciences, Inc., Redmond, Washington) and NMP22 test kit (Matritech, Newton, Massachusetts), and the differential sensitivity regarding the histological pattern of tumors. Materials and Methods: A total of 213 patients with clinical and/or imaging signs of bladder cancer provided a single voided urine sample for the bladder cancer antigen, BTA stat test and NMP22 before cystoscopy. Of these patients 95 were monitored for superficial bladder cancer, while the remaining 118 had no history of bladder cancer. All detected bladder tumors or suspicious lesions were resected transurethrally. A group of 21 age and sex matched healthy volunteers were also evaluated with the same tests. Results: Bladder cancer was confirmed histologically in 118 patients, of whom primary and recurrent tumors were in 68 and 50, respectively. The optimal cutoffs calculated with receiver operating characteristics curves were 8 units per ml. for NMP22 and 12 μg./l. for bladder cancer antigen. Overall sensitivity and specificity were 72.9% and 64.6% for the BTA stat test, 63.5% and 75.0% for NMP22, and 80.5% and 80.2%, respectively, for bladder cancer antigen. Bladder cancer antigen proved significantly more sensitive than NMP22 for detecting bladder cancer (p = 0.001) but not more than the BTA stat test, while the specificity of it was significantly higher than that of the BTA stat test (p = 0.009). Bladder cancer antigen had a sensitivity of 80.7% for stage Ta tumors, which was significantly higher than NMP22 (52.6%, p = 0.001) and the BTA stat test (57.9%, p = 0.01). In grade I tumors the sensitivity of bladder cancer antigen (70%) did not differ significantly than that of the BTA stat test (50%) and NMP22 (50%, p = 0.14). Bladder cancer antigen had the least false-positive results in patients with a history of bladder cancer and negative cystoscopy, and those with urological disease other than bladder cancer. Conclusions: Our data indicate that bladder cancer antigen may be a more potent diagnostic marker for bladder cancer than NMP22 and the BTA stat test based on the higher sensitivity for detecting low stage and low grade tumors, and the higher specificity. The contribution of these tests for detection of bladder cancer should still be considered adjunctive to cystoscopy. References 1 : Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology1995; 45: 387. Google Scholar 2 : Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol1996; 6: 272. Google Scholar 3 : Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer1995; 31A: 1840. Google Scholar 4 : Natural history of superficial bladder tumors: 10 to 20 years followup of treated patients. World J Urol1997; 15: 84. Google Scholar 5 : The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol1995; 153: 1823. Link, Google Scholar 6 : Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol1983; 14: 140. Google Scholar 7 : The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer1987; 60: 1423. Google Scholar 8 : Comparison of screening methods in the detection of bladder cancer. J Urol1999; 161: 388. Link, Google Scholar 9 : Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res1998; 4: 2511. Google Scholar 10 : The cell’s nucleus shapes up. Science1993; 259: 1257. Google Scholar 11 : Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol1996; 156: 363. Link, Google Scholar 12 : Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol1998; 159: 394. Link, Google Scholar 13 : Sensitivity and specificity of NMP22, telomerase and BTA in the detection of human bladder cancer. Urology1998; 52: 398. Google Scholar 14 : Comparative evaluation of the BTAstat test, NMP22 and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology2000; 55: 871. Google Scholar 15 : Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol1997; 31: 163. Google Scholar 16 : Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int1999; 84: 706. Google Scholar 17 : Keratins as biochemical markers of epithelial differentiation. Trends Genet1988; 4: 277. Google Scholar 18 : The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell1982; 31: 11. Google Scholar 19 : Clinical relevance of CYFRA 21–1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res1996; 16: 3793. Google Scholar 20 : Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology1997; 50: 349. Google Scholar 21 : Initial evaluation of urinary bladder cancer antigen as a tumor marker for bladder cancer. J Urol1999; 161: 1110. Link, Google Scholar 22 : Histological typing of urinary bladder tumors. International histological classification of tumours, No. 10. Geneva: World Health Organization1973. Google Scholar 23 : Staging of cancer at genitourinary sites. In: Manual for Staging of Cancer. Edited by . Philadelphia: J. B. Lippincott1988: 194. Google Scholar 24 : Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol1999; 162: 53. Link, Google Scholar 25 : Bladder cancer: natural history, tumor markers and early detection strategies. Semin Surg Oncol1997; 13: 299. Google Scholar 26 : Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol1999; 35: 52. Google Scholar 27 : Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol2000; 163: 1689. Abstract, Google Scholar 28 : Comparative sensitivity of urinary CYFRA 21–1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol1999; 162: 1951. Abstract, Google Scholar 29 : Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology2000; 55: 223. Google Scholar 30 : Noninvasive detection of bladder cancer with the BTA stat test. J Urol1999; 161: 443. Link, Google Scholar From the Departments of Urology and Immunology, University of Athens Medical School, Laikon Hospital and G. Papanicolaou Research Center, Saint Savas Hospital, Athens, Greece© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByCai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E and Bartoletti R (2018) Interleukin-6/10 Ratio as a Prognostic Marker of Recurrence in Patients With Intermediate Risk Urothelial Bladder CarcinomaJournal of Urology, VOL. 178, NO. 5, (1906-1912), Online publication date: 1-Nov-2007.Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G and Piazzini M (2018) Multiplex Polymerase Chain Reaction for Microsatellite Analysis of Urine Sediment Cells: A Rapid and Inexpensive Method for Diagnosing and Monitoring Superficial Transitional Bladder Cell CarcinomaJournal of Urology, VOL. 175, NO. 6, (2032-2037), Online publication date: 1-Jun-2006.GLAS A, ROOS D, DEUTEKOM M, ZWINDERMAN A, BOSSUYT P and KURTH K (2018) Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic ReviewJournal of Urology, VOL. 169, NO. 6, (1975-1982), Online publication date: 1-Jun-2003. Volume 166Issue 2August 2001Page: 470-475 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordstumor markersbladder neoplasmsantigensbiologicalMetricsAuthor Information ARIS GIANNOPOULOS More articles by this author THEODOROS MANOUSAKAS More articles by this author ANTONIA GOUNARI More articles by this author CONSTANTINOS CONSTANTINIDES More articles by this author HELEN CHOREMI-PAPADOPOULOU More articles by this author CONSTANTINOS DIMOPOULOS More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W2002605455 created "2016-06-24" @default.
• W2002605455 creator A5023440324 @default.
• W2002605455 creator A5053959705 @default.
• W2002605455 creator A5063248464 @default.
• W2002605455 creator A5076145446 @default.
• W2002605455 creator A5077378208 @default.
• W2002605455 creator A5089895606 @default.
• W2002605455 date "2001-08-01" @default.
• W2002605455 modified "2023-09-27" @default.
• W2002605455 title "COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORS" @default.
• W2002605455 cites W1529888204 @default.
• W2002605455 cites W1704450602 @default.
• W2002605455 cites W1964175172 @default.
• W2002605455 cites W1982131415 @default.
• W2002605455 cites W1983617790 @default.
• W2002605455 cites W1987558301 @default.
• W2002605455 cites W2003009773 @default.
• W2002605455 cites W2004856662 @default.
• W2002605455 cites W2006069963 @default.
• W2002605455 cites W2006481475 @default.
• W2002605455 cites W2016693266 @default.
• W2002605455 cites W2020647507 @default.
• W2002605455 cites W2031977829 @default.
• W2002605455 cites W2034000112 @default.
• W2002605455 cites W2054807115 @default.
• W2002605455 cites W2057784168 @default.
• W2002605455 cites W2067441234 @default.
• W2002605455 cites W2078799517 @default.
• W2002605455 cites W2085946824 @default.
• W2002605455 cites W2087085408 @default.
• W2002605455 cites W2093197634 @default.
• W2002605455 cites W2111442523 @default.
• W2002605455 cites W2145961594 @default.
• W2002605455 cites W2157760049 @default.
• W2002605455 cites W2167120646 @default.
• W2002605455 cites W2279476366 @default.
• W2002605455 doi "https://doi.org/10.1016/s0022-5347(05)65965-4" @default.
• W2002605455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11458049" @default.
• W2002605455 hasPublicationYear "2001" @default.
• W2002605455 type Work @default.
• W2002605455 sameAs 2002605455 @default.
• W2002605455 citedByCount "79" @default.
• W2002605455 countsByYear W20026054552012 @default.
• W2002605455 countsByYear W20026054552013 @default.
• W2002605455 countsByYear W20026054552014 @default.
• W2002605455 countsByYear W20026054552015 @default.
• W2002605455 countsByYear W20026054552016 @default.
• W2002605455 countsByYear W20026054552017 @default.
• W2002605455 countsByYear W20026054552018 @default.
• W2002605455 countsByYear W20026054552020 @default.
• W2002605455 countsByYear W20026054552021 @default.
• W2002605455 countsByYear W20026054552022 @default.
• W2002605455 countsByYear W20026054552023 @default.
• W2002605455 crossrefType "journal-article" @default.
• W2002605455 hasAuthorship W2002605455A5023440324 @default.
• W2002605455 hasAuthorship W2002605455A5053959705 @default.
• W2002605455 hasAuthorship W2002605455A5063248464 @default.
• W2002605455 hasAuthorship W2002605455A5076145446 @default.
• W2002605455 hasAuthorship W2002605455A5077378208 @default.
• W2002605455 hasAuthorship W2002605455A5089895606 @default.
• W2002605455 hasConcept C121608353 @default.
• W2002605455 hasConcept C126322002 @default.
• W2002605455 hasConcept C126894567 @default.
• W2002605455 hasConcept C142724271 @default.
• W2002605455 hasConcept C147483822 @default.
• W2002605455 hasConcept C203014093 @default.
• W2002605455 hasConcept C2779762690 @default.
• W2002605455 hasConcept C2780352672 @default.
• W2002605455 hasConcept C71924100 @default.
• W2002605455 hasConcept C77411442 @default.
• W2002605455 hasConceptScore W2002605455C121608353 @default.
• W2002605455 hasConceptScore W2002605455C126322002 @default.
• W2002605455 hasConceptScore W2002605455C126894567 @default.
• W2002605455 hasConceptScore W2002605455C142724271 @default.
• W2002605455 hasConceptScore W2002605455C147483822 @default.
• W2002605455 hasConceptScore W2002605455C203014093 @default.
• W2002605455 hasConceptScore W2002605455C2779762690 @default.
• W2002605455 hasConceptScore W2002605455C2780352672 @default.
• W2002605455 hasConceptScore W2002605455C71924100 @default.
• W2002605455 hasConceptScore W2002605455C77411442 @default.
• W2002605455 hasIssue "2" @default.
• W2002605455 hasLocation W20026054551 @default.
• W2002605455 hasLocation W20026054552 @default.
• W2002605455 hasOpenAccess W2002605455 @default.
• W2002605455 hasPrimaryLocation W20026054551 @default.
• W2002605455 hasRelatedWork W2010561882 @default.
• W2002605455 hasRelatedWork W2026671784 @default.
• W2002605455 hasRelatedWork W2040074305 @default.
• W2002605455 hasRelatedWork W2082766431 @default.
• W2002605455 hasRelatedWork W2088967662 @default.
• W2002605455 hasRelatedWork W2120561004 @default.
• W2002605455 hasRelatedWork W2381010098 @default.
• W2002605455 hasRelatedWork W2735230849 @default.
• W2002605455 hasRelatedWork W3179359475 @default.
• W2002605455 hasRelatedWork W2118673085 @default.
• W2002605455 hasVolume "166" @default.
• W2002605455 isParatext "false" @default.

• next